Cost-Benefit Analysis of Risperidone and Clozapine in the Treatment of Schizophrenia in Israel

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.13, Iss.2, 1998-02, pp. : 231-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach

By > >

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 69-80

Adis International

Access to resources Recommend Favorite

Cost-Benefit Analysis of First-Generation Antihistamines in the Treatment of Allergic Rhinitis

By Patrick W. Sullivan

PharmacoEconomics, Vol. 22, Iss. 14, 2004-01 ,pp. : 929-942

Adis International

Access to resources Recommend Favorite

Cost Analysis of the Treatment of Schizophrenia in the UK: A Simulation Model Comparing Olanzapine, Risperidone and Haloperidol

By Almond S.

PharmacoEconomics, Vol. 17, Iss. 4, 2000-04 ,pp. : 383-389

Adis International

Access to resources Recommend Favorite

Cost-Benefit Analysis of Amtolmetin-Guacil

By Belisari A. Mantovani L.G.

Clinical Drug Investigation, Vol. 21, Iss. 1, 2001-01 ,pp. : 47-58

Adis International

Access to resources Recommend Favorite

Cost-Benefit Analysis of Active Vaccination Campaigns Against Hepatitis A Among Daycare Centre Personnel in Israel

By Chodick G.

PharmacoEconomics, Vol. 19, Iss. 3, 2001-03 ,pp. : 281-291

Adis International

Access to resources Recommend Favorite